China SXT Pharmaceuticals Inc is a holding company mainly engaged in the research, development, manufacture, marketing and sales of Chinese traditional medicine products (TCMP). The Company sells different types of TCMP products, including Advanced TCMP and Regular TCMP. Advanced TCMP comprises of Directly-Oral-TCMP and After-Soaking-Oral TCMP. Regular TCMP is mainly for hospitals and drug stores for the treatment of various diseases or serving as dietary supplements. The Company sells its products under the brand Suxuantang.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
29/10/26	$3.640	-1.08%	44,820
28/10/26	$3.680	+3.66%	172,465
27/10/26	$3.550	+0.28%	237,051
26/10/26	$3.540	-13.66%	204,983
23/10/26	$4.100	-14.58%	227,414

Delayed Quote Nasdaq

More quotes

Real-time Estimate Cboe BZX 19:05:17 29/10/2026 +03			5-day change	1st Jan Change
3.640 ^USD	-1.09%		-24.16%	-100.00%

10-08	Top Premarket Decliners	MT
08-05	Top Premarket Decliners	MT

Market Cap	48.63K 43.63K 40.34K 36.53K 68.25K 4.63M 69.07K 482K 192K 2.42M 182K 179K 7.69M	P/E 2025 *	-	P/E 2026	-
Enterprise Value	-27.15M -24.36M -22.52M -20.4M -38.11M -2.59B -38.57M -269M -107M -1.35B -102M -99.74M -4.3B	EV / Sales 2025	9.01x	EV / Sales 2026	-22.6x
Free-Float	97.74%	Yield 2025 *	-	Yield 2026	-

Markets		Quality
Nasdaq	SXTC	Delayed
Tradegate	2RY3	Real-time
CBOE	SXTC	Real-time
Deutsche Boerse AG	2RY3	Delayed

10-08	Top Premarket Decliners	MT
08-05	Top Premarket Decliners	MT
07-30	Top Premarket Gainers	MT
07-28	Top Premarket Decliners	MT
07-24	Top Premarket Decliners	MT
07-23	Top Premarket Decliners	MT
07-22	Top Premarket Gainers	MT
07-03	China SXT Pharmaceuticals, Inc. announced that it expects to receive $28.56 million in funding	CI
07-01	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2026	CI
01-08	Top Midday Gainers	MT
01-01	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended September 30, 2025	CI
31/07/25	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2025	CI
28/03/25	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended September 30, 2024	CI

China SXT Pharmaceuticals, Inc. Stock

Stocks

SXTC

VGG2161P1817

Pharmaceuticals

Valuation: China SXT Pharmaceuticals, Inc.

Chart: China SXT Pharmaceuticals, Inc.

Latest news: China SXT Pharmaceuticals, Inc.

Analysts' recommendations: China SXT Pharmaceuticals, Inc.

Press Releases: China SXT Pharmaceuticals, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: China SXT Pharmaceuticals, Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

08-05	China SXT Pharmaceuticals, Inc. Announces Share Consolidation	AQ
07-25	Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)	AQ
07-23	China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering	AQ
07-01	China SXT Pharmaceuticals : Annual Report for Fiscal Year Ending March 31, 2026 (Form 20-F)	PU
03-24	China SXT Pharmaceuticals, Inc. Announces Share Re-classification	AQ

1 day	-1.09%
1 week	-24.16%
Current month	-98.79%
1 month	-98.70%
3 months	-99.13%
6 months	-99.98%
Current year	-100.00%

1 week	3.28	4.55
1 month	3.28	959
Current year	3.28	8,376,215.05
1 year	3.28	8,376,215.05
3 years	3.28	61,324,376.2
5 years	3.28	5,100,000,000
10 years	3.28	10,000,000,000

Manager	Title	Age	Since
Sze Beng Lim CEO	Chief Executive Officer	-	20/01/2025
Feng Zhou CEO	Chief Executive Officer	34	04/07/2017
Xiaodong Pan DFI	Director of Finance/CFO	49	31/01/2022

Director	Title	Age	Since
Feng Zhou CHM	Chairman	34	04/07/2017
Jun Zheng BRD	Director/Board Member	49	31/12/2018
Xiaodong Ji BRD	Director/Board Member	57	22/05/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CHINA SXT PHARMACEUTICALS, INC.	-1.09%	-24.16%	-100.00%	-100.00%	48.63K
ELI LILLY AND COMPANY	+6.28%	+4.61%	+68.02%	+141.63%	1,148B
JOHNSON & JOHNSON	+1.37%	+2.52%	+47.03%	+86.60%	652B
ABBVIE INC.	+1.17%	+1.30%	+28.32%	+103.61%	505B
ROCHE HOLDING AG	+0.74%	+2.32%	+54.07%	+66.27%	384B
MERCK & CO., INC.	+4.56%	+0.06%	+70.16%	+43.48%	348B
NOVARTIS AG	+2.48%	+2.64%	+34.29%	+56.30%	294B
ASTRAZENECA PLC	+2.08%	+0.17%	+3.52%	+27.25%	264B
AMGEN INC.	+1.45%	+2.55%	+57.21%	+74.28%	244B
GILEAD SCIENCES, INC.	+1.37%	+2.54%	+36.02%	+107.26%	197B
Average	+2.04%	-3.71%	+29.87%	+60.67%	403.72B
Weighted average by Cap.	+3.08%	+1.50%	+49.63%	+92.92%

	2025	2026
Net sales	1.74M 1.56M 1.44M 1.31M 2.44M 166M 2.47M 17.27M 6.88M 86.76M 6.53M 6.4M 275M	1.14M 1.02M 944K 855K 1.6M 108M 1.62M 11.29M 4.5M 56.72M 4.27M 4.18M 180M
Net income	-3.3M -2.96M -2.74M -2.48M -4.64M -315M -4.69M -32.76M -13.05M -165M -12.4M -12.14M -523M	-6.21M -5.57M -5.15M -4.66M -8.71M -591M -8.81M -61.54M -24.51M -309M -23.29M -22.79M -982M
Net Debt	-17.25M -15.48M -14.31M -12.96M -24.22M -1.64B -24.51M -171M -68.15M -860M -64.74M -63.38M -2.73B	-27.2M -24.4M -22.56M -20.43M -38.18M -2.59B -38.64M -270M -107M -1.36B -102M -99.92M -4.3B